You are here

  • Home
  • Archive
  • Volume 10, Issue 12
  • Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Citation Tools

Article menu

This article has a correction. Please see:

Immunotherapy biomarkers
Original research
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Han X, Tang X, Zhu H, et al
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Journal for ImmunoTherapy of Cancer 2022;10:e004952. doi: 10.1136/jitc-2022-004952